Alnylam plunges after deaths in rare disease trial
Biotech axes revusiran due to safety concerns.
X
Alnylam plunges after deaths in rare disease trial
https://pharmaphorum.com/news/anylam-ends-heart-drug-development/
Biotech axes revusiran due to safety concerns.
